Microdosing Psychedelics: Cognitive Impairment and Mood Myths

Microdosing Psychedelics: Cognitive Impairment and Mood Myths

A recent comprehensive review published on June 28, 2026, challenges the widely held belief that psychedelic microdosing enhances cognitive function and mood. The review, which followed rigorous methodological standards, found no significant cognitive or mood benefits from microdosing substances like lysergic acid diethylamide (LSD) or psilocybin. Instead, it identified a small but significant impairment in cognitive control, contradicting popular claims.

Mechanisms and Context of Microdosing

Psychedelic microdosing involves taking sub-perceptual doses of psychedelics, typically ⩽20 μg of LSD or ⩽3 mg of psilocybin. It has gained popularity as a potential intervention for mood and cognitive enhancement. However, the evidence base is methodologically diverse and susceptible to expectancy bias. This review synthesized data from 14 studies involving 1,614 participants, revealing that microdosing does not enhance cognitive function and may impair cognitive control.

Implications for Policy and Research

The findings from this review underscore the necessity for more rigorous, expectancy-controlled trials before microdosing can be recommended as a therapeutic intervention. Current evidence does not support the cognitive enhancement claims associated with microdosing, and observed mood benefits are not replicated under placebo-controlled conditions. This highlights the need for adequately powered, preregistered trials to establish reliable outcomes.

Risks and Unknowns

While short-term tolerability of microdosing appears acceptable, the review highlights potential long-term risks, particularly concerning cardiovascular health and 5-HT 2 B receptor activation. These risks remain uncharacterized and warrant further investigation. The small but significant impairment in cognitive control also raises concerns about the safety of microdosing, especially in contexts requiring high cognitive performance.

Looking Forward: The Need for Rigorous Trials

As the interest in psychedelic microdosing continues to grow, it is crucial to prioritize rigorous scientific research to establish its efficacy and safety. This review serves as a call to action for researchers to conduct well-designed, expectancy-controlled trials that can provide clear and reliable evidence. Until such evidence is available, clinicians and policymakers should exercise caution in recommending microdosing as a therapeutic intervention.